Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%
Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its IPO last June. Speaking at an investor conference, a Caris executive identified by Chief Scientific
MarketBeat ·